Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MAT9001
Omega 3 pentaenoic acid · 1 trial · 1 indication
Percent change in triglycerides from baseline to end of treatment in the pharmacodynamic population
| Arm | Type | Description |
|---|---|---|
| Omega-3 pentaenoic acid (MAT9001) | EXPERIMENTAL | 2g MAT9001 capsules twice daily with meals |
| Icosapent ethyl (Vascepa) | ACTIVE_COMPARATOR | 2g Vascepa capsules twice daily with meals |
| Name | Type | Description |
|---|---|---|
| Omega 3 pentaenoic acid | DRUG | Encapsulated omega-3 pentaenoic acid |
| icosapent ethyl | DRUG | Encapsulated omega-3 acid ethyl esters |
Inclusion Criteria: * Male or female, ≥18 y of age * Judged to be in generally good health * Fasting triglycerides ≥150 mg/dL to ≤499 mg/dL during screening * Body mass index of ≥20.0 kg/m2 * No clinically significant findings in a 12-lead ECG or physical examination * Willing and able to undergo t...
Omega 3 pentaenoic acid is an investigational small molecule being developed by Matinas Biopharma Holdings, Inc. for hypertriglyceridemia, a metabolic condition marked by elevated triglycerides in the blood. It is a free-fatty acid formulation of an omega-3 fatty acid and has been studied in a Phase 2 clinical trial.
Omega 3 pentaenoic acid is being developed for the treatment of hypertriglyceridemia, a metabolic disorder characterized by high blood triglyceride levels. Its clinical evaluation has focused on adults with this condition. It is investigational and has not been approved for commercial use.
Omega 3 pentaenoic acid is being developed by Matinas Biopharma Holdings, Inc., which trades under the ticker MTNB. The company sponsored the clinical program evaluating a free-fatty acid formulation of the compound in adults with hypertriglyceridemia.
Omega 3 pentaenoic acid has completed a Phase 2 clinical trial and remains an investigational agent. It has not been approved by the FDA. The Phase 2 study was an active-controlled, randomized trial that enrolled 100 adults with hypertriglyceridemia in the United States.
Omega 3 pentaenoic acid has been studied in one clinical trial, NCT04177680, titled Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia. The Phase 2 trial is completed, enrolled 100 participants, was randomized and active-controlled, and was conducted in the United States.